Cong L, Zhang B N, Xie L X
Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao 266071, China.
Zhonghua Yan Ke Za Zhi. 2023 Aug 11;59(8):666-672. doi: 10.3760/cma.j.cn112142-20221007-00502.
With the continual advancement of gene editing technology, gene therapy has been increasingly explored as a potential treatment option for both hereditary and acquired diseases. Due to its unique physiological and anatomical characteristics, the eye has emerged as an optimal target for gene therapy. In fact, ophthalmology was among the first clinical fields to obtain approval for gene therapy. Despite the widespread development of gene therapy targeting ocular surface and corneal diseases in recent years, a systematic review of these projects is still lacking. Thus, this review aims to comprehensively summarize the research progress and clinical application of gene therapy for ocular surface and corneal diseases, providing valuable guidance for future research and clinical translation.
随着基因编辑技术的不断进步，基因治疗作为一种针对遗传性和后天性疾病的潜在治疗选择，受到了越来越多的探索。由于眼睛独特的生理和解剖特征，它已成为基因治疗的理想靶点。事实上，眼科是最早获得基因治疗批准的临床领域之一。尽管近年来针对眼表和角膜疾病的基因治疗发展广泛，但仍缺乏对这些项目的系统综述。因此，本综述旨在全面总结眼表和角膜疾病基因治疗的研究进展及临床应用，为未来的研究和临床转化提供有价值的指导。
